Adaptive Biotechnologies targets 30%+ clonoSEQ test volume growth in 2026 while expanding margins and data partnerships
Source: SeekingAlpha
2026-02-06 12:15:23 ET
More on Adaptive Biotechnologies
- Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
- Adaptive Biotechnologies Corporation 2025 Q4 - Results - Earnings Call Presentation
- Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Adaptive Biotechnologies GAAP EPS of -$0.09 beats by $0.09, revenue of $71.7M beats by $10.8M
- Adaptive Biotechnologies Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Adaptive Biotechnologies targets 30%+ clonoSEQ test volume growth in 2026 while expanding margins and data partnerships
Adaptive Biotechnologies Corporation
NASDAQ: ADPT
ADPT Trading
-6.48% G/L:
$14.93 Last:
814,830 Volume:
$15.48 Open:
ADPT Latest News
February 05, 2026 04:05:00 pm
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
January 22, 2026 04:05:00 pm
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
ADPT Stock Data
$2,393,790,148
142,894,616
2.45%
99
N/A
Biotechnology & Life Sciences
Healthcare
US
Seattle
